Tempest Therapeutics, Inc. (TPST)

NASDAQ: TPST · Real-Time Price · USD

9.34

+0.53 (6.02%)

At close: Aug 13, 2025, 4:00 PM

9.46

+0.12 (1.28%)

After-hours: Aug 13, 2025, 6:01 PM EDT

Tempest Therapeutics Employees

Tempest Therapeutics had 24 employees as of December 31, 2024. The number of employees increased by 7 or 41.18% compared to the previous year.

Employees

24

Change (1Y)

7

Growth (1Y)

41.18%

Revenue / Employee

n/a

Profits / Employee

-$1,795,792

Market Cap

38.18M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	24	7	41.18%
Dec 31, 2023	17	-2	-10.53%
Dec 31, 2022	19	2	11.76%
Dec 31, 2021	17	3	21.43%
Dec 31, 2020	14	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

TPST News

2 days ago - Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
6 weeks ago - Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China - GlobeNewsWire
2 months ago - Tempest Announces $4.6 Million Registered Direct Offering of Common Stock - GlobeNewsWire
2 months ago - Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC - GlobeNewsWire
3 months ago - Tempest Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
3 months ago - Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting - GlobeNewsWire
4 months ago - Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP - GlobeNewsWire
4 months ago - Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value - GlobeNewsWire